SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (22585)6/21/1998 7:29:00 PM
From: Hippieslayer  Read Replies (1) | Respond to of 32384
 
What! Are you on drug? Lgnd is never mentioned in big left wing news papers! Just kidding. Good find even though I don't get the paper. I'll see if I can find it on line....sorry, on line version of NYT doesn't have it.

Good article about the Bennet boys, though.



To: Sleepman who wrote (22585)6/22/1998 5:10:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Dan, Thanks for the heads up. Actually, LGND is indirectly mentioned a third time. Michael Sporn is also quoted and he did the study which showed that Panretin could prevent breast cancer and synergize with Tamoxifen. That work set the stage for the two ongoing combination trials (Panretin and Tamoxifen), as well as all of the Targretin data (Sporn was thanked in the acknowledgement section of the "Beyond Tamoxifen" paper).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News